Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 697 clinical trials
Featured trial
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.

BRAF
combinations
pd-1 inhibitor
cancer
immunologic adjuvant
  • 0 views
  • 19 Dec, 2022
  • 6 locations
Featured trial
BLOOD SAMPLE COLLECTION- UNTREATED MELANOMA

MELANOMA, ALSO KNOWN AS MALIGNANT MELANOMA, IS A TYPE OF CANCER THAT DEVELOPS FROM THE PIGMENT-CONTAINING CELLS KNOWN AS MELANOCYTESUP OF FAT IN THE LIVER.  

  • 104 views
  • 03 Oct, 2019
  • 1 location
Featured trial
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma (015-104)

Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma (015-104)

  • 456 views
  • 23 Nov, 2020
  • 1 location
Featured trial
CTSU/ECOG E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High-Risk Melanoma

CTSU/ECOG E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High-Risk Melanoma

  • 266 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

  • 140 views
  • 25 Mar, 2021
  • 1 location
A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas

a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.

  • 0 views
  • 20 Oct, 2022
  • 6 locations
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)

Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Neoadjuvant L19IL2/L19TNF- Pivotal Study (Pivotal)

Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.

hepatitis b antigen
malignant melanoma of skin
neutrophil count
BRAF
serum ldh
  • 123 views
  • 26 Apr, 2022
  • 21 locations
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), melanoma, renal, bladder, small-cell lung cancer (SCLC), gastric/esophageal cancer, and high-level microsatellite

monoclonal antibodies
primary cancer
lung cancer
  • 57 views
  • 07 Oct, 2022
  • 16 locations
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy (MINER)

enrolled in the trial: Non-Small Cell Lung Cancer (NSCLC), Head and neck cancer, Melanoma, Bladder cancer, Other tumor types when Immuno-Oncology agent

  • 12 views
  • 26 Apr, 2022
  • 2 locations